Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features
Lung Cancer Aug 29, 2019
Khorrami M, Jain P, Bera K, et al. - In this study, researchers examined whether major pathological response (MPR: defined as ≤ 10% of residual viable tumor, assessed at the time of surgery) to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients could be predicted via assessing CT derived intratumoral and peritumoral texture and nodule shape features. They randomly divided 90 selected patients with stage III NSCLC, who were treated with chemoradiation prior to surgical resection, into two equal sets, one for training and one for independent testing. They extracted the radiomic texture and shape features from within the nodule (intra) and from the parenchymal regions immediately surrounding the nodule (peritumoral). Findings revealed 13 stable and predictive intratumoral and peritumoral radiomic texture features that were predictive of MPR. The likelihood of MPR, OS and DFS to chemoradiation was seemed to be correlated with texture features extracted within and around the lung tumor on CT images.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries